The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | High-risk AML: the 2022 ELN risk classification and challenges in this patient population
Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the use of the 2022 ELN risk classification system to diagnose high-risk acute myeloid leukemia (AML), highlighting remaining challenges in this patient population, and commenting on the potential of magrolimab in high-risk patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Steering committee: AbbVie; DSMB: Aptevo, Epizyme, Syntrix, Takeda; Advisory board: AvenCell, Cellularity, CTI Pharma, GSK, Kura Onc, Rigel; Focus group: BerGenBio; Grand rounds: Jazz
